TK-001 is a genetic vaccine vs an Oncogene target:

  • well-known and validated target in Oncology
  • Immunotherapy Clinical trials with other technologies conducted/in progress
  • Preliminary clinical trial showed tolerability and safety for patients

Where we are:

  • Preclinical studies completed
  • Vectors (both Adeno and plasmid DNA) for human clinical use constructed
  • Biomarker assays in place

Main Cancer Targets:

  • Breast
  • Ovarian
  • Head and Neck

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.